Citations

Clear

6273 citation(s) found for "To, Andrew".

CYP2B6 polymorphisms and suicidal behaviour in people living with HIV treated with efavirenz-containing combination antiretroviral therapy: a global case–control study
Arenas-Pinto, Alejandro, Nordwall, Jacqueline , Carey, Dianne , Fletcher, Courtney V., Thompson, Greg, Reilly, C. S., Safo, Sandra E. , Grund, Birgit , Arenas‐Pinto, Alejandro , Fletcher, Courtney Vail , Badley, Andrew D. , Lundgren, Jens

Mayo Clinic

Frontiers in Pharmacology | April 13, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fphar.2026.1734919 | PMID 42051257 Get It

Background We analysed the association between host genetic risk scores (GRSs) predicting efavirenz (EFV) plasma levels and exposure and suicidal behaviours in participants in one of several global antiretroviral therapy (ART) clinical trials linked to the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Methods We conducted a matched case–control study (two controls per case) on suicide or grade-4 suicidal ideation/attempts or depression. Cases and controls were matched by EFV initiation strategy, study, and follow-up time. CYP2B6-based GRS classified participants as extensive, intermediate, or slow metabolisers. EFV and its metabolites (8-hydroxy-EFV and 7-hydroxy-EFV) were measured in plasma. Conditional logistic regression was used to analyse the associations between GRS categories, EFV levels, and suicidal behaviour. Results Among 74 cases and 146 controls, 128 (58.2%) started EFV-containing first-line treatment. Of the treatment-experienced participants, 35% were on EFV at entry. Pre-existing psychiatric conditions and recreational drug-use were more common in cases (16.2%, 25.7%) than in controls (0.7%, 9.6%). On comparing cases to controls, more cases were extensive metabolisers (52% vs. 45%), but there were fewer slow metabolisers (8% vs. 13%). The unadjusted odds ratio (OR) for suicidal behaviour per one more minor allele was 0.76 (95% CI: 0.49–1.18). The OR for being a case vs. a control was 0.57 (95% CI: 0.38–0.86) per doubling of the EFV plasma level. Conclusion CYP2B6-based GRS for cytochrome P450 enzymatic activity appeared not to be associated with suicidal behaviour in individuals living with HIV treated with EFV-containing ART combinations. CYP2B6-based GRS effectively predicted EFV exposure, but suicidal behaviour appeared more likely in extensive (normal) metabolisers.
Stopping Spin at the Source: Learning From an Example in Obesity
Brown, Andrew W. , Jensen, Michael D. , Allison, David B. , Jensen, Michael , Allison, David B

Mayo Clinic

Obesity | April 12, 2026 | Volume: 34 | Issue: 6 | Pages: 1183-1186

10.1002/oby.70159 | PMID 41967833 Get It

Bronchial Mucosal Abnormalities in Idiopathic Subglottic Stenosis
Ring, Sydney , Bowen, Andrew J. , Griffin, Tessa C. , Ferguson, J. Scott , Dailey, Seth H. , Bowen, Andrew Jay , Griffin, Tessa

Mayo Clinic

The Laryngoscope | April 12, 2026 | Volume: 136 | Issue: 8 | Pages: 3527-3533

10.1002/lary.70543 | PMID 41966683 Get It

ABSTRACT Objectives Investigate synchronous lower airway findings during bronchoscopy in idiopathic subglottic stenosis (iSGS). Methods Retrospective analysis of bronchoscopic images from adult iSGS patients (January 2018–June 2021). Images were reviewed for pits, depressions, nodules, and striations distal to the cricotracheal junction. Results Forty‐eight female patients; mean age 56 years. Comorbidities: gastroesophageal reflux 34%, hypertension 34%, diabetes mellitus 25%. All patients had pits and depressions; striations in 48/48, with both longitudinal and transverse in 32/48 (66.7%), transverse only in 13/48 (27.1%), and longitudinal only in 3/48 (6.3%). Spirometry available in 32; 60% showed normal or mild–moderate fixed obstruction. Four patients had FEV 1 /FVC < 0.7; two had asthma, one COPD, and one no obstructive diagnosis; none were smokers. Conclusion Bronchial mucosal abnormalities are prevalent in iSGS and may indicate distal airway involvement. Routine flexible bronchoscopy should be considered during evaluation and surveillance. Level of Evidence 4.
Therapy-specific motoneuron activation with epidural and dorsal root ganglion stimulation in spinal cord injury
Anders, Jennifer , Gill, Megan L., Fernandez, K. A. , Veith, Daniel D. , Linde, Margaux B. , Mills, Candee J. , Thoreson, Andrew R. , Hagedorn, Jon, Bendel, Mark A. , Iqbal, Rayyan A. , Grahn, Peter J. , Asp, Anders J , Fernandez, K A , Hagedorn, Jon M, Sayenko, Dimitry G , Solinsky, Ryan , Grahn, Peter J , Hagedorn, Jonathan M. , Bendel, Mark A., Sayenko, Dimitry G. , Solinsky, Ryan , Zhao, Kristin D.

Mayo Clinic

Journal of Neurophysiology | April 11, 2026 | Volume: 135 | Issue: 5 | Pages: 1220-1230

10.1152/jn.00438.2025 | PMID 41963069 Get It

Epidural and dorsal root stimulation have emerged as promising therapies to restore function after spinal cord injury. However, how each modality uniquely or jointly engages spinal circuits remains unclear. To address this, we analyzed leg electromyography (EMG) responses to epidural stimulation (ES) and dorsal root ganglia stimulation (DRGS) delivered to the lumbosacral cord in the same individuals.
Building capacity for translational team science: digital badging as a pathway to professionalization
Glauber, Kristine M. , Sweeney, Whitney A. , Boguslav, Mayla R., Fox, Andrew T., Hartstein, Madison, Hildreth, Laura , Lee-Chavarria, Diana , McCormack, Wayne T. , Mendell, Angela, Molano, Jennifer Rose V. , Risser, Heather J. , Billings, Heather A, Billings, Heather , Boguslav, Mayla R. , Lobb, Rebecca , Mendell, Angela M. , Brasier, Allan R.

Mayo Clinic

Frontiers in Psychology | April 10, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fpsyg.2026.1771863 | PMID 42039008 Get It

Effective translation relies on high performance teams integrating diverse disciplines to bring new drugs, medical devices, diagnostics or behavioral interventions into improved health. Despite substantial advancements informed by the Science of Team Science (SciTS), challenges remain in effective translational team (TT) operations, while limited institutional, scholarly, and practitioner legitimacy of team science expertise constrains efforts to address them. Here, we describe an essential member of the TT, the Team Science Professional (TSP). Serving as a team educator and facilitator of team interventions, the TSP plays a pivotal role in facilitating effective team performance. Current challenges faced by this nascent profession are defining career pathways and establishing competencies needed for expert performance. To address these challenges, the authors, representing a spectrum of academic universities organized as a special interest group (SIG) of the Association of Clinical and Translational Science (ACTS), propose a suite of individualized, standardized and pathway-selective micro-credentials (digital badges). Digital badges in “Team Science (TS) Fundamentals,” “TS Practitioner,” “TT Trainer” and “TT Intervention Expert” are described, along with preliminary feasibility and usability evaluations of the submission process. These stackable credentials provide a customizable, portable recognition of skills and help advance career pathways for TSPs. In so doing, the Digital Badge Initiative will enhance the capacity of translational science “Hubs” such as those supported by Clinical and Translational Science Awards to conduct effective and rigorous translation. Moving forward, the ACTS TSP SIG will be examining the impact of digital badging on standardization and its effect on career recognition and retention.
A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma
Lee, Hans C. , Plattel, Wouter J. , Sborov, Douglas W, Lentzsch, Suzanne , Spencer, Andrew, Niesvizky, Rubén, Trudel, Suzanne , Vij, Ravi, Rasche, Leo , Talpes, Mihaela , Eggert, Tobias , Kapoor, Prashant , Ailawadhi, Sikander, Harrison, Simon J , Lentzsch, Suzanne , Minnema, Monique C , Rasche, Leo , Upreti, Vijay V , Xia, Qing , Lee, Hans C , Sborov, Douglas W. , Spencer, Andrew , Mollee, Peter , Vij, Ravi , Zhou, Di , Ailawadhi, Sikander

Mayo Clinic

Blood | April 8, 2026 | Volume: 148 | Issue: 2 | Pages: 199-212

10.1182/blood.2025032044 | PMID 41950113 Get It

Abstract The B-cell maturation antigen (BCMA)–targeting bispecific T-cell engager pavurutamab (AMG 701) directs the cytotoxic T-cell response toward multiple myeloma (MM) cells. This phase 1/1b, open-label, dose-exploration and dose-expansion study evaluated the safety, tolerability, and efficacy of pavurutamab monotherapy in patients with triple-class relapsed/refractory MM (RRMM). Pavurutamab (5-18 000 μg) was administered IV weekly with step-up dosing in week 1. Overall, 172 patients received at least 1 dose of pavurutamab; 73 received the recommended phase 2 dose (RP2D; 18 000 μg), with 2 different step-up dosing regimens in phase 1b. Twelve patients had dose-limiting toxicities, which included cytokine release syndrome (CRS) and increased transaminases; none of which occurred at the RP2D. The most frequently reported treatment-emergent adverse events included CRS (74.4%), anemia (61.0%), neutropenia (47.1%), and hypophosphatemia (45.3%). Grade ≥3 infections were noted in 60 patients (34.9%). The overall response rate (ORR) was 46.5% among all patients and 65.8% (very good partial response [VGPR] or better, 60.3%) among 73 patients treated at the RP2D. At median follow-up of 17.2 months, median duration of response (DOR) was 36.6 months (95% confidence interval [CI], 22.3 to not estimable). Median progression-free survival (PFS) for all patients was 5.5 months (95% CI, 2.8-10.1) and 16.8 months (95% CI, 5.0 to not estimable) with the RP2D. Pavurutamab exposure generally increased in a dose-proportional manner, with high soluble BCMA levels correlating with lower exposure level. The acceptable safety profile, pharmacokinetics, and preliminary efficacy of pavurutamab supports anti-BCMA T-cell engager therapy in heavily pretreated patients with RRMM. This trial was registered at www.clinicaltrials.gov as NCT03287908.
SGLT2 Inhibitors and GLP‐1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta‐Analysis
Frazee, Erin N. , Garcia‐Nieves, Yessie A., Eder, Ty H., Gerberi, Dana , Kashani, Kianoush B., Kattah, Andrea G. , Liu, Kathleen D., McCoy, Rozalina G., Murphy, Daniel P. , Rule, Andrew D., Frazee, Erin N , Wieruszewski, Patrick M , Nieves, Yessie Ann Garcia, Johnson, Evan C., Kashani, Kianoush , May, Heather P. , McCoy, Rozalina G. , Rule, Andrew D. , Wieruszewski, Patrick M.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | April 8, 2026 | Volume: 46 | Issue: 5 | Pages: No page available

10.1002/phar.70137 | PMID 41947629 Get It

ABSTRACT Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are nephroprotective and their use is recommended for adults with chronic kidney disease (CKD). The role of SGLT2i and GLP‐1 RAs in patients with acute kidney injury (AKI) is unknown. This systematic review aimed to estimate the effect of SGLT2i or GLP‐1 RAs on clinical outcomes in AKI. We systematically searched Embase, MEDLINE, Scopus, Web of Science Core Collection, and clinical trials registries for observational studies and clinical trials from database inception to July 3, 2025. Included studies evaluated adults (≥ 18 years) with AKI during a hospitalization and compared patients subsequently exposed to either SGLT2i or GLP‐1 RAs to a non‐exposed control group. Random effects meta‐analyses were performed. Six studies related to SGLT2i (five observational, one randomized trial) and one related to GLP‐1 RAs (one observational) met eligibility criteria ( N = 432,048 patients). SGLT2i/GLP‐1 RA exposure was associated with lower odds of major adverse kidney events (MAKE) (OR 0.63, 95% CI 0.46–0.86) and all‐cause mortality [odds ratio (OR) 0.36, 95% confidence interval (CI) 0.21–0.62] compared to controls. The odds for kidney replacement therapy were lower with SGLT2i therapy in the three studies where it was evaluated (OR 0.61, 95% CI 0.40–0.93). Sensitivity analyses restricted to SGLT2i data were consistent with the overall findings [MAKE OR 0.63 (95% CI 0.42–0.95); Mortality OR 0.34 (95% CI 0.18, 0.65)]. Exposure to SGLT2i or GLP‐1 RAs after AKI, examined primarily in observational studies, was associated with improved clinical outcomes. These findings are promising and warrant evaluation in randomized clinical trials.
Risk Factors for Postoperative Cerebrospinal Fluid Leak Following Endoscopic Transsphenoidal Surgery for Craniopharyngioma: A Multicenter Cohort Study with a Contemporary Surgeon Practice Survey
Celda, María Peris, Karsy, Michael, Evans, James J, Kim, Albert H, Kim, W, Bergsneider, Marvin , Pacione, Donato , Gardner, Paul A. , Mukherjee, Raj, Liu, Connor J. , Cheok, Stephanie , Zwagerman, Nathan T. , Christenson, Charles, Blackburn, Spiros, Kshettry, Varun R, Wu, Kyle C, Prevedello, Daniel, Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Zada, Gabriel, Benjamin, Carolina , Catalino, Michael Paul, Mamelak, Adam N, Furlan, André Beer, Zenonos, Georgios, Mendoza, Michelle Magana, Little, Andrew S, Gompel, Jamie J., Karsy, Michael , Palit, Sandhya R. , Shinya, Yuki , Karsy, Michael , Evans, James J., Chicoine, Michael , Kim, Albert H , Patel, Bhuvic , Kim, Won Bae , Gardner, Paul, Mukherjee, Debraj , Liu, C P, Blackburn, Spiros , Kshettry, Varun R. , Rennert, Robert C , Couldwell, William T. , Morshed, Ramin A. , Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Zada, Gabriel , BENJAMIN, CAROLINA, Mamelak, Adam N. , Zenonos, Georgios A. , Little, Andrew S. , Gompel, Jamie J. Van

Mayo Clinic

No container title available | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9285619/v1 | PMID 41994110 Get It

Abstract Purpose: This multicenter, multi-surgeon retrospective study aimed to identify risk factors for postoperative cerebrospinal fluid (CSF) leak following endonasal resection of craniopharyngioma, while evaluating the "perception gap" through a surgeon survey. Methods: A retrospective review was conducted on 416 patients who underwent endoscopic transsphenoidal surgery (ETS) for craniopharyngioma from 20 institutions. Factors were compared between patients with and without postoperative CSF leak, and between Early (2007-2015) and Late (2016-2025) Epochs. Complementing the clinical data, a survey of 19 neurosurgeons captured expert perspectives on risk stratification and management strategies. Results: Overall postoperative CSF leak rate was 13.5% (56/416 patients). Univariate analysis identified predominantly cystic tumors (34% vs. 21%, p = 0.034)and intraoperative lumbar drain (LD) use ( p < 0.028) as associated with postoperative CSF leak. BMI ( p = 0.587), prior surgery ( p = 0.576), and tumor size ( p = 0.363) were not significant. In the multivariable analysis, LD use was associated with a higher postoperative CSF leak rate (OR 1.91, 95% CI 1.06–3.46; p = 0.030). Between Epochs, nasoseptal flap (NSF) utilization increased from 70.7% to 87.6% ( p <0.001). NSF was protective (OR 0.28, 95% CI 0.07–0.92; p = 0.037) in the Early Epoch; no factors were significant in the Late Epoch. The surgeons’ survey identified prior surgery and intraoperative high flow leaks as primary risks; however, their LD protocols diverged from clinical data. Conclusion: Despite increased use of NSF, CSF leak persists. The study highlights a significant divergence between expert perception and clinical data regarding lumbar drains.
Toward actionable interventions in human aging (12th ARDD meeting, 2025)
Dekan, Aleksandr , Lore, Sierra , Yoon, Ye Eun, Sjöholm, Aisyah, Terskikh, Alexey V. , Cuervo, A. M., Georgievskaya, Anastasia , Heinz, Andrea , Adams, Andrew, Tsai, Andy P. , Murray, Anna, Brunet, Anne , Harten, Anne Marije van, Spier, Avi, Shenhar, Ben , Clasen, Berthil, Volbracht, Christiane , Kuppe, Christoph, Cookson, Clive, Banila, Cristiana , Cai, Daisy, Lamming, Dudley W. , Rudnic, Edward, Samra, Elias Bou , Verdin, Eric, Fagagna, Fabrizio d’Adda di, Zmudze, Garri, Jasper, Heinrich, Jang, In Hwa, Lemaitre, J. M., Betts-LaCroix, Joe , Newman, John C. , Kawamura, Kazuto , Schaal, Kennedy Matsagas, Egerton, Kitsu, Fortney, Kristen , Hartenstein, Lars, Niedernhofer, Laura, Katsimpardi, Lida , Melton, Lisa , Ferrucci, Luigi, Sylow, Lykke, Demaria, Marco , Guasch-Ferré, Marta, Borch-Jensen, Martin, Kholin, Maxim, Antonov, Michael, Deleidi, Michela , Mérad, Miriam , Meldal, Morten, Topors, Mourad, Venkatesan, Murali, LeBrasseur, Nathan K., Anzinger, Niklas, Fedichev, Peter O, Kohlhaas, Paul, Mullen, Peter J., Singhal, Priya , Cabo, Raquel, Montgomery, Rusty L. , Rosenzweig-Lipson, Sharon, Jakimov, Sergey, Austad, Steven N. , White, Todd, Zuber, Tom, Rozmaric, Tomaz , Wyss-Coray, Tony, Gladyshev, Vadim N., Sinatti, Vanessa V. C., Wang, Weilan, Harborne, William, Wang, Xing Li, Suh, Yousin , Lee, Y., Koch, Zane, Scheibye-Knudsen, Morten, Niedernhofer, Laura J. , Wyss‐Coray, Tony , Niedernhofer, Laura J , Lamming, Dudley W , Deleidi, Michela , Wyss-Coray, Tony , Bakula, Daniela , Tyshkovskiy, Alexander , Cuervo, Ana M , Seluanov, Andrei , Murray, Anna , Pedersen, Bente Klarlund , Schumacher, Björn , Kennedy, Brian Keith , Suetta, Charlotte , Kuppe, Christoph , Ewald, Collin Y. , Valenzano, Dario Riccardo , Rudnic, Edward M., Teeling, Emma C. , Verdin, Eric , Fang, Evandro Fei , Fagagna, Fabrizio d’Adda di , Galkin, Fedor , Jasper, Heinrich , Jang, In Hwa , Han, Jing‐Dong J. , Justice, Jamie N. , Hoeijmakers, Jan H.J. , Ramos, Javier María Peralta , Lemaı̂tre, Jean-Marc , Aerssens, Jeroen , Belmonte, Juan Carlos Izpisúa , Abdelmohsen, Kotb , Knudsen, Lotte Bjerre , Ferrucci, Luigi , Sylow, Lykke , Schafer, Marissa , Guasch‐Ferré, Marta , Levitt, Michael R. , Meldal, Morten , Fedichev, Peter O. , Mullen, Peter J. , Cabo, Rafael de, Houtkooper, Riekelt H. , Smith, Ryan , Rosenzweig‐Lipson, Sharon, Horvath, Steve , Rando, Thomas A. , White, Todd, Tammela, Tuomas , Gladyshev, Vadim N. , Sinatti, Vanessa V C , Liu, Xiaodong , Suh, Yousin , Koch, Zane , Zhavoronkov, Alex , Scheibye‐Knudsen, Morten

Mayo Clinic

Aging | April 6, 2026 | Volume: 18 | Issue: 1 | Pages: 282-302

10.18632/aging.206368 | PMID 41944812 Get It

Impact of Frailty on Outcomes Following Mitral Transcatheter Edge‐to‐Edge Repair: A Propensity‐Score Matched Analysis
Jain, Hritvik , Patel, Nandan , Jain, Jyoti, Ahmed, Mushood, Goyal, Aman, Goldsweig, Andrew M., Ahmed, Mushood , Goyal, Aman , Ahmed, Mushood , Goyal, Aman , Baqal, Omar , Jain, Hritvik , Jain, Jyoti, Baqal, Omar J , Goldsweig, Andrew M.

Mayo Clinic

Catheterization and Cardiovascular Interventions | April 6, 2026 | Volume: 107 | Issue: 7 | Pages: 2234-2239

10.1002/ccd.70587 | PMID 41937235 Get It

Summary Frailty is independently associated with significantly higher 1‐year mortality and MACCE following MTEER. Frail patients also demonstrated increased risks of HF exacerbation, major bleeding, and readmission. Incorporating frailty assessment into pre‐procedural evaluation may improve risk stratification and guide personalized management strategies.